Literature DB >> 8973627

The CD7- T cell subset represents the majority of IL-5-secreting cells within CD4+CD45RA- T cells.

U Reinhold1, L Liu, J Sesterhenn, S Schnautz, H Abken.   

Abstract

Absence of CD7 is a stable phenotype in a subset of normal human T cells. Most circulating CD7- T cells express the CD4CD45RO+CD45RA- memory phenotype. We analysed CD4+CD45RA- peripheral blood lymphocytes that were separated into CD7+ and CD7- for their in vitro cytokine secretion in response to different stimuli. The CD4+CD7- subpopulation was found to secrete significantly higher levels of IL-5 compared with the CD4+CD7- subset upon stimulation with ionomycin/phorbol myristate acetate (PMA) plus anti-CD28 MoAbs. In contrast to IL-5 secretion, IL-4 and interferon-gamma (IFN-gamma) secretion was not significantly different in CD7+ and CD7- T cells upon stimulation in vitro. The data indicate that the CD4+CD7- T cell represents the majority of IL-5-secreting cells within the population of CD4+CD45RA- memory T cells. Since CD4+CD7- T cells were found to be enriched in various skin lesions associated with eosinophilic infiltration, the results of our study support the hypothesis that skin-infiltrating CD7- T cells are one of the major sources of IL-5 responsible for the development of eosinophilic inflammation in certain skin diseases.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8973627      PMCID: PMC2200620          DOI: 10.1046/j.1365-2249.1996.d01-873.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  2 in total

Review 1.  CD4+ CD7- T cells: a separate subpopulation of memory T cells?

Authors:  U Reinhold; H Abken
Journal:  J Clin Immunol       Date:  1997-07       Impact factor: 8.317

2.  Accumulation of CD4+CD7- T cells in inflammatory skin lesions: evidence for preferential adhesion to vascular endothelial cells.

Authors:  L Liu; H Abken; C Pföhler; G Rappl; W Tilgen; U Reinhold
Journal:  Clin Exp Immunol       Date:  2000-07       Impact factor: 4.330

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.